# Endo Hsd T Trial

> Suggests a 3- to 6‑month trial of testosterone dosing to achieve a mid‑normal premenopausal value in a reference assay for postmenopausal women with properly diagnosed HSDD and no contraindications. Triggered when a postmenopausal woman requests therapy for low sexual desire after appropriate HSDD workup and exclusion of contraindications.

- Skill: `dromlakhani/endo-hsd-t-trial` (Agent Skill)
- Install (CLI): `npx skillmds add dromlakhani/endo-hsd-t-trial`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-hsd-t-trial/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-08-19
- Page: https://skillmd.com/skills/dromlakhani/endo-hsd-t-trial

---


# Suggest a testosterone trial for diagnosed HSDD

## STEP 1 — Gather Information
Confirm postmenopausal status, diagnose HSDD per DSM‑5 after ruling out medical, psychiatric, and relationship causes, obtain baseline total testosterone (or free testosterone) using a validated assay, and screen for contraindications (androgen‑sensitive malignancy, uncontrolled hyperandrogenism, pregnancy, breastfeeding, significant liver disease).

## STEP 2 — Rule In / Rule Out
Is the patient a postmenopausal woman with a confirmed HSDD diagnosis and no contraindications to testosterone? If **yes**, proceed to Step 3; if **no**, do not initiate a testosterone trial and address underlying causes or consider alternative therapies.

## STEP 3 — Classify or Stratify
Compare baseline testosterone to the mid‑normal premenopausal reference range (e.g., 20‑30 ng/dL total T). If baseline is **below** this range, the patient is a candidate for a testosterone trial; if baseline is **within or above** the range, consider non‑hormonal approaches or avoid testosterone to prevent excess.

## STEP 4 — Decide
Initiate a 3‑ to 6‑month trial of a non‑oral testosterone preparation (e.g., transdermal patch delivering ~300 µg/day, gel, or cream) titrated to achieve a mid‑normal premenopausal level; schedule follow‑up at 3–6 weeks to assess symptoms, side effects, and testosterone level, then every 3 months thereafter, and discontinue after 6 months if no meaningful improvement in sexual desire.

## Clinical Guardrails / Mimics / Pitfalls
Monitor for signs of androgen excess (acne, hirsutism, voice deepening, clitoromegaly); avoid oral testosterone or DHEA formulations due to variable dosing and safety data; do not exceed physiological dosing that yields supraphysiological levels; avoid use in women with history of breast or endometrial cancer, uncontrolled liver disease, or pregnancy; reassess need for continued therapy at 6 months and stop if ineffective.

## Concrete Clinical Example
A 58‑year‑old postmenopausal woman reports 6 months of distressing low sexual desire; HSDD is confirmed after negative depression screen, normal thyroid, and stable relationship; baseline total testosterone is 12 ng/dL (below mid‑normal premenopausal ~25 ng/dL); she has no contraindications. She starts a transdermal testosterone patch 300 µg/day. At 4‑week visit she reports improved desire and no androgenic signs; therapy is continued for up to 6 months with periodic testosterone checks, then stopped if no further benefit.

**Source:** Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2260